The United States prostate cancer treatment devices market will progress at a rate of 5.6% in the years to come and reach USD 157.1 million by 2030. The industry has a lot to do with the increasing number of prostate cancer cases registered in the nation each year, as stated by a market research institution, P&S Intelligence.
The radiation category will witness highest rate in the years to come, mainly because of its high preference for treatment of patients over further devices.
Broad acceptance and adoption of radiotherapy and launch of advanced equipment are some of the key factors powering the growth of the industry.
Hospitals are the largest end-users will witness highest rate in the years to come. This has a lot to do with the intricate nature of treatment for prostate cancer, mostly done in hospitals in the existence of trained healthcare specialists.
These healthcare settings provide diagnosis and treatment of prostate cancer and offer the best possible care to the patients.
California dominated the U.S. prostate cancer treatment devices market. This trend will continue in the years to come. This can be credited to considerably large count of hospitals in the state and growing count of prostate cancer patients looking for the possible treatment.
Increasing acceptance of robotic prostatectomy is one of the key trends in the industry.
Robot-assisted radical prostatectomy is becoming popular because of the high acceptance rate in the U.S. It is a type of surgery that makes use of the surgical robotic equipment for removing entire prostate. This approach has the advantage of small incision, decreased pain, less loss of blood, lower rate of transfusion, and less hospital stay, as opposed to conservative open surgery with similar cure rate.
The government of the U.S., every year spends a considerable portion of its gross domestic product on healthcare. The NHEA stated that healthcare spending in the U.S. raised by 4.3% to reach USD 3.3 trillion in 2016, which supplementary increased to 5.4% in 2017.
This increasing spending on the healthcare is snowballing the affordability of the management and treatment of diseases, which is further contributing toward the development of the market in the industry.
For example, in October 2017, the NCI SPORE, a program designed for converting scientific findings into clinical settings-based outcomes.
This also facilitates the expansion of novel technologies and studies for gaining a better comprehending of monitoring, deterrence, analysis, and treatment of dissimilar diseases.
It plays a key role in proceeding translational cancer research with academia, industry further government agencies, and the international research community.
Consequently, increasing R&D programs as well as growing initiatives by the government will also drive the market growth.
Technological advancements have a lot to do with the increasing demand for prostate cancer treatment devices in the U.S.
Comments
Post a Comment